Becton Dickinson and Co Stock (US0758871091): Valuation Check As Shares Lag 2026 Highs

Becton Dickinson and Co shares remain well below their 2026 starting level, putting valuation and fundamentals in focus for US investors as the medical technology group trades around the mid-$140s.

Responsible: ad hoc news Markets & Valuation Desk. Reviewed prior to publication on June 12, 2026 at 9:50 PM ET. Details in the imprint.

Becton Dickinson and Co stock continues to trade at a notable discount to its 2026 opening level, putting the spotlight on the company’s valuation, earnings profile and dividend appeal for US retail investors. According to MarketBeat data, the NYSE-listed shares closed at $147.40 on June 11, 2026, down 0.26 percent on the day and modestly lower in after-hours trading. From the start of the year, when Becton Dickinson and Co was at $194.11, the stock has retreated by roughly 24 percent, leaving it well below both its 52-week peak of $187.35 and the Street’s current consensus price target.

BDX valuation in focus after year-to-date slide

The pronounced drawdown in Becton Dickinson and Co’s share price in 2026 has brought its valuation and fundamentals into sharper focus, especially given its profile as a large, diversified medical technology company with a long operating history. MarketBeat lists the company’s market capitalization at approximately $40.62 billion at the June 11 close, reflecting its status as a major player in the global medtech space and a significant component of US healthcare equity exposure for many portfolios. With the shares at $147.40, Becton Dickinson and Co is currently valued at a price-to-earnings ratio of 37.32 based on trailing metrics, positioning the stock in a premium bracket compared with many mature healthcare peers that trade on lower multiples.

That earnings multiple sits alongside a dividend profile that may appeal to income-focused investors who can tolerate the valuation. MarketBeat data indicates that Becton Dickinson and Co’s dividend yield stands at about 2.85 percent at the present share price level, which is meaningfully above the current yield of the broader S&P 500 but below what some high-yield defensive names offer. The combination of a mid-single-digit yield, a historically consistent dividend record and a relatively high earnings multiple underscores that a portion of the market’s pricing still reflects expectations for steady earnings growth and durable cash flows, despite the sizeable year-to-date share price decline.

Analyst expectations also play into the valuation picture. MarketBeat reports that the consensus 12-month price target for Becton Dickinson and Co currently stands at $183.64. Relative to the $147.40 closing price on June 11, that implies an upside potential of roughly 24.6 percent if the stock were to reach the collective target set by covering analysts. While price targets are not guarantees, the gap between the present market price and consensus expectations highlights that many on Wall Street see room for the stock to recover some ground, provided the company executes on its growth and margin plans.

Behind the headline target range sits a more nuanced analyst stance. According to MarketBeat, Becton Dickinson and Co has earned a consensus rating of "Hold," derived from 7 buy ratings, 8 hold ratings and 1 sell rating across the brokerage community following the name. The average rating score is cited at 2.38 on a scale where higher numbers typically indicate more bullish conviction. This distribution suggests that while a meaningful minority of analysts still recommend accumulating the stock, the majority view is more cautious, reflecting a balance between the company’s defensive qualities and concerns about valuation, competition or earnings trajectory.

MarketBeat further notes that Becton Dickinson and Co scores highly in its internal ranking framework, with the company said to have scored higher than 99 percent of firms evaluated and to sit in 7th place out of 863 stocks in the broad medical sector universe covered by the platform. While this scoring system is specific to MarketBeat’s methodology, it does underscore that, on various metrics such as profitability, stability and analyst sentiment, Becton Dickinson and Co remains a relatively strong name in the medtech landscape even during a period of share price underperformance. For valuation-driven investors, this mix of strong fundamental scoring and weaker recent price action may be a core part of the debate around the stock.

Trading dynamics also offer context for how the market is digesting the stock’s valuation. MarketBeat lists average daily trading volume at about 2.54 million shares, compared with an actual volume of 1.64 million shares on June 11. The lower-than-average turnover on that day, combined with the modest 0.26 percent price decline, indicates that there has not been a rush for the exits despite the longer-term trend of weakness since January. For many institutional and retail participants, that can be a sign that the market is in a wait-and-see mode, reassessing Becton Dickinson and Co’s growth profile and capital allocation as new information emerges over the course of 2026.

In terms of risk and reward, the year-to-date decline of roughly 24.1 percent from $194.11 to $147.40 has meaningfully compressed the stock’s price relative to its 52-week high of $187.35 but still leaves Becton Dickinson and Co trading above its 52-week low of $127.59. For valuation watchers, this sets the shares in the lower mid-range of their one-year band, a position that can attract interest from investors looking for established healthcare names that are no longer pricing in perfection but still trade at a premium to the broader market. How compelling that setup is will depend on individual views about earnings resilience, competitive positioning and the broader macro backdrop for healthcare spending.

Overall, the latest pricing and analyst data suggest that Becton Dickinson and Co is in a consolidation phase in which valuation, dividend support and expectations for future growth are being weighed against a relatively rich earnings multiple and a notable drawdown from early-2026 levels. Investors watching the stock will likely continue to track upcoming earnings reports, guidance updates and sector-wide medtech sentiment to reassess whether the current mid-$140s level adequately reflects the company’s long-term fundamentals.

Key facts on the Becton Dickinson and Co stock

• Name: Becton, Dickinson and Company
• Industry: Medical technology and medical devices
• Headquarters: Franklin Lakes, New Jersey, United States
• Core markets: Hospital care, diagnostics, life sciences and medication management solutions
• Revenue drivers: Sales of medical devices, diagnostic systems and laboratory equipment to healthcare providers and laboratories worldwide
• Listing: New York Stock Exchange, ticker symbol BDX
• Trading currency: US dollars (USD)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.